Bank of America’s NovoCure NVCR Stock Holding History

Bank of America’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-134,100	Closed	-$4M	–	8468
2024 Q4	$4M	Buy	134,100 +89,000	+197%	+$1.88M	﹤0.01%	3800
2024 Q3	$705K	Sell	45,100 -75,000	-62%	-$1.36M	﹤0.01%	5275
2024 Q2	$2.06M	Hold	120,100	–	–	﹤0.01%	4423
2024 Q1	$1.88M	Sell	120,100 -78,300	-39%	-$1.15M	﹤0.01%	4493
2023 Q4	$2.96M	Buy	198,400 +60,700	+44%	+$812K	﹤0.01%	4014
2023 Q3	$2.22M	Buy	137,700 +95,600	+227%	+$2.76M	﹤0.01%	4143
2023 Q2	$1.75M	Sell	42,100 -57,900	-58%	-$3.6M	﹤0.01%	4327
2023 Q1	$6.01M	Buy	100,000 +60,000	+150%	+$4.79M	﹤0.01%	3360
2022 Q4	$2.93M	Hold	40,000	–	–	﹤0.01%	3910
2022 Q3	$3.04M	Hold	40,000	–	–	﹤0.01%	3892
2022 Q2	$2.78M	Hold	40,000	–	–	﹤0.01%	3993
2022 Q1	$3.31M	Hold	40,000	–	–	﹤0.01%	4053
2021 Q4	$3M	Sell	40,000 -24,300	-38%	-$2.44M	﹤0.01%	4165
2021 Q3	$7.47M	Hold	64,300	–	–	﹤0.01%	3156
2021 Q2	$14.3M	Buy	64,300 +40,000	+165%	+$7.78M	﹤0.01%	2459
2021 Q1	$3.21M	Buy	24,300 +20,800	+594%	+$3.29M	﹤0.01%	3817
2020 Q4	$606K	Hold	3,500	–	–	﹤0.01%	4876
2020 Q3	$390K	Hold	3,500	–	–	﹤0.01%	4902
2020 Q2	$208K	Hold	3,500	–	–	﹤0.01%	5220
2020 Q1	$236K	Buy	+3,500	New	+$277K	﹤0.01%	4995

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Bank of America's NVCR Position: Q1 2026 in Review

Bank of America reduced its NovoCure (NVCR) stake by 50% in Q1 2026, selling an estimated $2.16M and leaving 170,013 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Bank of America first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $36.3M in Q2 2021. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Bank of America held 170,013 shares of NovoCure worth $1.85M as of Q1 2026.
Bank of America sold 172,940 NovoCure shares in Q1 2026, an estimated $2.16M.
NovoCure made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4167 holding.
Bank of America first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
Bank of America's NovoCure position peaked at $36.3M in Q2 2021.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.